Loading...
Loading...
ELVN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 24.2M |
| Operating I/L | -24.2M |
| Other Income/Expense | 3.5M |
| Interest Income | 3.5M |
| Pretax | -20.8M |
| Income Tax Expense | -3.5M |
| Net Income/Loss | -20.8M |
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of small molecule kinase inhibitors for cancer treatment. The company's pipeline includes ELVN-001, currently in a Phase 1 clinical trial for chronic myeloid leukemia, and ELVN-002, which is undergoing a Phase 1 clinical trial for cancers with abnormal HER2 gene. These small molecule inhibitors are designed to target specific pathways in cancer cells, offering potential therapeutic benefits. Enliven Therapeutics generates revenue through the development and commercialization of these innovative cancer treatments, aiming to address unmet medical needs and improve patient outcomes.
